PharmaShots | Incisive News in 3 Shots

Subscribe Now

Novartis

Novartis Presents Results of Kesimpta (ofatumumab) in P-III (ASCLEPIOS I/II) and (ALITHIOS) Open-Label Extension Trial for RMS at EAN 2022

Novartis Presents Results of Kesimpta (ofatumumab) in P-III (ASCLEPIOS I/II) and (ALITHIOS) Open-Label Extension Trial for RMS at...

June 28, 2022

Novartis Publishes Results from Two and Three-Copy Cohorts of Zolgensma in P-III (SPR1NT) Trial for Spinal Muscular Atrophy in the Nature Medicine

Novartis Publishes Results from Two and Three-Copy Cohorts of Zolgensma in P-III (SPR1NT) Trial for Spinal Muscular Atrophy in the...

June 20, 2022

Novartis Presents Results of Tafinlar (dabrafenib) + Mekinist (trametinib) in P-II/III (TADPOLE) Trial for BRAF V600 Low-Grade Gliomas at ASCO 2022

Novartis Presents Results of Tafinlar (dabrafenib) + Mekinist (trametinib) in P-II/III (TADPOLE) Trial for BRAF V600 Low-Grade Gli...

June 8, 2022

Novartis’ Kymriah (tisagenlecleucel) CAR-T Cell Therapy Receives the US FDA’s Approval for the Treatment of Follicular Lymphoma

Novartis’ Kymriah (tisagenlecleucel) CAR-T Cell Therapy Receives the US FDA’s Approval for the Treatment of Follicular Lymphoma

May 30, 2022

Insights+: The US FDA New Drug Approvals in April 2022

Insights+: The US FDA New Drug Approvals in April 2022

May 19, 2022

Novartis Updated Exploratory OS Analysis of Kisqali (ribociclib) in P-III (MONALEESA-3) Trial for the Treatment of HR+/HER2- Advanced Breast Cancer

Novartis Updated Exploratory OS Analysis of Kisqali (ribociclib) in P-III (MONALEESA-3) Trial for the Treatment of HR+/HER2- Advan...

May 5, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us